The main products for this category is the unique single-use sampling bag systems allowing safe and aseptic sampling from any type of sterilizable sampling valve.
The Keofitt Sampling Bags have all been developed as single-use solutions to the cumbersome and difficult task of taking a representative sample and bringing it safe and clean from the sampling point to the laboratory.
At the same time the Keofitt Sampling Bags offer convenience and safety in use and higher efficiency in the work process. No prior assembly or cleaning of any components; no glass or metal component is introduced to the production area.
All Keofitt Sampling Bags are made of medical grade plastics complying with all relevant FDA, USP and ISO regulations for both the food and the pharmaceutical/biotech industries.
The Keofitt Sampling Bags are delivered separately packed and sterilized by irradiation. In each carton a Radiation Certificate and a Certificate of Conformity are enclosed.
The Keofitt Sampling Bags are manufactured following strict in-process testing including a test for endotoxins.
The proper performance of all Keofitt Sampling Bags is supported by a number of validation documents covering SIP’ability, biocompatibility, extractables, USP Class VI, endotoxins, mechanical and chemical properties etc.
The product range comprises 4 types:
Contact details:
KEOFITT A/S
Website: link name www.keofitt.dkE-mail:info@keofitt.dk
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
May 12th 2025Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines (Sealy 2021). Formulators need to consider a number of factors when scaling up novel LNP systems. These include flow rates that affect LNP particles, solvent removal, risk factors when changing equipment, and the impact of tangential flow filtration sensitivity. In this technical note, we discuss these factors and what needs to be considered when developing a cost- and time efficient large-scale process.